Pityriasis Rosea and Immunosuppressive Drugs [Letter]. [PDF]
Clin Cosmet Investig DermatolDrago F, Fidanzi C, Ciccarese G.
europepmc +1 more source
A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system. [PDF]
Arch Dermatol ResMashoudy KD, Ye-Tay J, Nouri K.
europepmc +1 more source
Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature. [PDF]
Dermatol Reports, 2023 Veraldi S +3 more
europepmc +1 more source
Pityriasis rosea and pityriasis rosea-like eruption: The distinction is relevant for diagnostic and prognostic reasons. [PDF]
J Family Community MedCiccarese G, Serviddio G, Drago F.
europepmc +1 more source
Reply to "the significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations" by Ciccarese G. et al. [PDF]
Dermatol Ther, 2022 Martora F +4 more
europepmc +1 more source
Pityriasis Rosea and Immunosuppressive Drugs [Response to Letter]. [PDF]
Clin Cosmet Investig DermatolWu H, Ji QJ, Xu YY, Zhu JW.
europepmc +1 more source
Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19. [PDF]
Indian Dermatol Online J, 2022 Singh BSTP, Kar BR, Agrawal I.
europepmc +1 more source
COVID-19-associated pityriasis rosea in children: Case report and literature review. [PDF]
Clin Case Rep, 2022 Khalili M +3 more
europepmc +1 more source
Pityriasis Rosea Eruption Following the Administration of Oxford-AstraZeneca Vaccine. [PDF]
CureusMarghalani S +4 more
europepmc +1 more source
Challenges in designing studies assessing birth complications and spontaneous abortion in pregnant patients with pityriasis rosea. [PDF]
J Am Acad DermatolOng MM, Lipner SR.
europepmc +1 more source